İki Uçlu Bozuklukta Metabolik Sendrom Yaygınlığının Mevsimsel Değişimi
Öz
Anahtar Kelimeler
Kaynakça
- Meltzer HY, Davidson M, Glassman AH, Vieweg WV. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. J Clin Psychiatry 2002; 63: 25-29.
- Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K, Lentz B, Keller P. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther. 2003; 10: 348- 355.
- Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotic. Am J Psychiatry 2003; 160: 290-296.
- McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46: 273-281.
- Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis. 2004; 192: 19-27.
- Correll CU, Frederickson AM, Kane JM, Manu P. Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotics drugs. J Clin Psychiatry 2006; 67: 575-583.
- Sicras A, Rejas J, Navarro R, Serrat J, Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord. 2008; 10: 607-616.
- van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342-348.
Ayrıntılar
Birincil Dil
Türkçe
Konular
-
Bölüm
-
Yazarlar
Kürşat Altınbaş
Bu kişi benim
Aslı Enez Darçın
Bu kişi benim
Sinan Gülöksüz
Bu kişi benim
Timuçin Esat Oral
Bu kişi benim
Yayımlanma Tarihi
1 Şubat 2012
Gönderilme Tarihi
8 Ekim 2014
Kabul Tarihi
-
Yayımlandığı Sayı
Yıl 2012 Cilt: 2 Sayı: 2